ARCHIVES

NIH Director: NCI’s Special Authorities “More Of A Negative Than A Positive”

This article is from The Cancer Letter archive.

Vol. 36 No. 22 | June 11, 2010

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

In Brief: Charles Heidelberger, Sol Spiegelman Both Die of Cancer; Robert Wittes New CTEP Director

January 28, 1983

For Research Projects In Cancer Therapy

March 1, 1996

NCAB Ok’s Funding First Three Years Of Diet Trial

December 7, 1990

NCI Spearheads Asbestos Alert

June 16, 1978

ASCO Board Accepts Plan To Establish New Bethesda Headquarters, Hire Chief Officer

April 23, 1993